Nexalin Technology, Inc.

Nexalin Technology, Inc. has filed a definitive proxy statement for its Annual Meeting of Stockholders scheduled for August 11, 2026. Key proposals for stockholder consideration include the election of five directors, approval of a 2026 Equity Incentive Plan, and authorization for a reverse stock split ranging from 1-for-2 to 1-for-100, with an aggregate limit of 1-for-250. Additionally, stockholders will vote on authorizing 10 million shares of preferred stock, providing for officer exculpation, and ratifying the appointment of independent auditors.

Dr. Victor Fontenelle Bastos de Lima, an investigator for Nexalin's Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 for research on Nexalin's DIFS™ platform. The award-winning study evaluated the platform for insomnia symptoms in patients with comorbid anxiety, demonstrating significant and durable improvements in sleep quality. This independent scientific recognition strengthens the visibility of Nexalin's non-invasive neurostimulation platform as the company prepares for its product launch in Brazil, where it already holds ANVISA approval for anxiety, depression, and insomnia.

Nexalin Technology, Inc. adopted its Second Amended and Restated Bylaws, effective June 16, 2026. These amendments revise advance notice procedures for stockholder nominations and business, modify special meeting nomination processes, and update various stockholder meeting provisions. Notably, the quorum standard for stockholder meetings was lowered from a majority to one-third of outstanding shares, and procedures for stockholder action by written consent were introduced. The bylaws also include revisions to Board structure, director terms, officer provisions, and add a forum selection clause for certain corporate claims.

Nexalin Technology announced that two clinical abstracts showcasing its proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. Data from an 8-week pilot clinical trial demonstrated a 77.8% anxiety response rate, significant improvements in depressive symptoms and insomnia, and enhanced quality of life, with no serious adverse events. These findings strengthen the scientific viability of Nexalin's non-invasive neurostimulation approach as the company prepares for global commercial initiatives and advances its FDA De Novo regulatory pathway.

The United States Patent and Trademark Office issued U.S. Patent No. 12,629,519 to Nexalin Technology, Inc. This patent, titled "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia," provides intellectual property protection for Nexalin's core dynamic frequency stimulation method through 2042. This strengthens the company's long-term competitive position in non-invasive frequency-based deep-brain neurostimulation and supports its HALO Clarity and NeuroCare strategies for large, underserved markets.

Nexalin Technology announced that the U.S. House Appropriations Committee's report language directs the Department of Veterans Affairs (VA) to support additional research into non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury (TBI). This language, advocated by Nexalin America, is part of the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill, which passed the U.S. House. Nexalin believes this directive validates its pioneering work in the field and could accelerate research pathways and long-term adoption of its DIFS™ technology within the VA, building on its ongoing clinical research at UC San Diego.

Nexalin Technology, Inc. announced the closing of its acquisition of PONM, Inc. for $1.3 million, payable in Nexalin common stock. This acquisition grants Nexalin ownership of PONM's digital health platform and an exclusive license to its proprietary software, which supports the HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic. The platform is crucial for Nexalin's planned FDA pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026, and enhances control over its digital infrastructure. Additionally, GreenLight Ventures, the seller, has become a significant equity holder in Nexalin and entered into a strategic partnership to provide ongoing support.

Nexalin Technology reported a significant decline in Q1 2026 revenue to $14,950, down 63.6% year-over-year, with net loss increasing to $2.10 million. The company disclosed substantial doubt about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. Additionally, Nexalin received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement. On a positive note, the FDA formally accepted the Q-Submission for its Gen-2 SYNC system for Alzheimer's and dementia.

Nexalin Technology announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics, reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia. The study found that patients treated with Nexalin's 15 mA, 77.5 Hz Deep Intracranial Frequency Stimulation (DIFS™) experienced a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7, while the sham group showed no significant change. This publication provides mechanistic support for Nexalin's proprietary DIFS™ technology and further validates its non-pharmacologic treatment strategy for mental health issues.

Nexalin Technology, Inc. has entered into a Scope of Work agreement with Lindus Health Limited, a UK-based clinical research organization. Under this agreement, Lindus Health will conduct the pivotal clinical trial for Nexalin's HALO Clarity device. The company will pay Lindus Health approximately $944,820 in direct fees, structured on a milestone basis, along with monthly pass-through expenses. This agreement marks a significant step forward in the development of the HALO Clarity device.